Save_our_sight_RNIB_campaign_report

Following this, it is reviewed by the National Institute for Health and Clinical Excellence (NICE) who look at the cost-effectiveness of the drug. Currently one anti-VEGF treatment (Lucentis) has been approved by the MHRA and NICE, while another is being used on the NHS (Avastin) but is unlicensed and has never been approved for use in the eye. ................
................